<p>Rocket Pharmaceuticals（纳斯达克代码：RCKT - 获取免费报告）在周五向客户和投资者发布的研究报告中，投资分析师 Leerink Partners 将其目标价格从 9.00 美元下调至 7.00 美元，Benzinga 报道。该券商目前对这家生物技术公司的股票给予 “市场表现” 评级。Leerink Partners 的目标价格意味着该股票相较于之前的收盘价有 118.41% 的潜在上涨空间。</p>
<p>获取 <strong>Rocket Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>3 只准备大幅上涨的小型股</li>
</ul>
<p>其他一些股票分析师也对 RCKT 发表了评论。瑞银集团将 Rocket Pharmaceuticals 的目标价格从 12.00 美元下调至 5.00 美元，并在 6 月 17 日的研究报告中对该股票给予 “买入” 评级。Canaccord Genuity Group 将 Rocket Pharmaceuticals 的目标价格从 11.00 美元下调至 10.00 美元，并在 7 月 25 日的报告中对该股票给予 “买入” 评级。Chardan Capital 在 8 月 20 日的报告中重申了对 Rocket Pharmaceuticals 的 “买入” 评级，并设定了 11.00 美元的目标价格。美国银行在 8 月 20 日的报告中将 Rocket Pharmaceuticals 的评级从 “中性” 上调至 “买入”，并将该股票的目标价格从 4.00 美元提高至 10.00 美元。最后，Needham &amp; Company LLC 在 7 月 24 日的报告中重申了对 Rocket Pharmaceuticals 的 “持有” 评级。八位股票研究分析师对该股票给予 “买入” 评级，八位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “持有”，共识目标价格为 16.67 美元。</p>
<p><strong>阅读我们最新的 RCKT 股票分析</strong></p>
<h2>Rocket Pharmaceuticals 股票表现</h2>
<p>Rocket Pharmaceuticals 的股票在周五下跌 0.01 美元，报 3.21 美元。该公司的股票交易量为 623,434 股，而其平均交易量为 3,511,637 股。该公司的市值为 3.4582 亿美元，市盈率为-1.28，贝塔值为 0.60。该公司的速动比率为 6.39，流动比率为 6.39，债务与股本比率为 0.05。该公司的 50 日移动平均价格为 3.19 美元，200 日移动平均价格为 4.37 美元。Rocket Pharmaceuticals 的股价在过去一年内最低为 2.19 美元，最高为 18.89 美元。</p>
<p>Rocket Pharmaceuticals（纳斯达克代码：RCKT - 获取免费报告）最近一次发布财报是在 8 月 7 日。该生物技术公司报告本季度每股收益为（0.59 美元），低于市场共识预期的（0.57 美元），差额为（0.02 美元）。去年同期，该公司每股收益为（0.74 美元）。分析师平均预计 Rocket Pharmaceuticals 在本年度的每股收益为-2.83 美元。</p>
<h2>Rocket Pharmaceuticals 的内部活动</h2>
<p>在相关消息中，内部人士 Jonathan David Schwartz 在 8 月 14 日的交易中出售了 11,161 股该股票。这些股票的平均售价为 3.02 美元，总价值为 33,706.22 美元。出售后，该内部人士直接持有 224,094 股公司股票，价值 676,763.88 美元。这笔交易代表其持股比例减少了 4.74%。该出售在向 SEC 的法律文件中披露，文件可在此链接查看。此外，首席法律顾问 Martin Wilson 在 8 月 14 日的交易中出售了 12,109 股该股票。这些股票的平均售价为 3.02 美元，总交易额为 36,569.18 美元。出售完成后，首席法律顾问持有 137,054 股公司股票，价值 413,903.08 美元。这代表其持股比例减少了 8.12%。该出售的披露信息可以在这里找到。在过去的九十天里，内部人士共出售了价值 107,159 美元的 35,450 股公司股票。公司内部人士持有公司股票的 24.76%。</p>
<h2>Rocket Pharmaceuticals 的机构交易</h2>
<p>最近，一些对冲基金买入和卖出了该股票的股份。Victory Capital Management Inc.在第一季度将其在 Rocket Pharmaceuticals 的持股增加了 16.1%。Victory Capital Management Inc.现在拥有 11,929 股该生物技术公司的股票，价值 80,000 美元，此前在上个季度又购买了 1,658 股。三菱 UFJ 资产管理有限公司在第一季度将其在 Rocket Pharmaceuticals 的持股增加了 8.4%。三菱 UFJ 资产管理有限公司现在拥有 21,885 股该生物技术公司的股票，价值 146,000 美元，此前在上个季度又购买了 1,689 股。中国泛海资产管理有限公司在第一季度将其在 Rocket Pharmaceuticals 的持股增加了 10.7%。中国泛海资产管理有限公司现在拥有 21,388 股该生物技术公司的股票，价值 143,000 美元，此前在上个季度又购买了 2,059 股。HighTower Advisors LLC 在第一季度将其在 Rocket Pharmaceuticals 的持股增加了 16.6%。HighTower Advisors LLC 现在拥有 20,700 股该生物技术公司的股票，价值 138,000 美元，此前在上个季度又购买了 2,952 股。最后，亚利桑那州退休系统在第一季度将其在 Rocket Pharmaceuticals 的持股增加了 15.3%。亚利桑那州退休系统现在拥有 22,852 股该生物技术公司的股票，价值 152,000 美元，此前在上个季度又购买了 3,026 股。目前 98.39% 的股票由机构投资者和对冲基金持有。</p>
<h2>Rocket Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Rocket Pharmaceuticals, Inc 及其子公司是一家处于后期阶段的生物技术公司，专注于开发针对罕见且严重疾病的基因疗法。它拥有三个临床阶段的外源性慢病毒载体项目，分别针对范可尼贫血，这是一种导致骨髓中血细胞生产减少或产生有缺陷血细胞的遗传缺陷；白细胞粘附缺陷-I，这是一种导致免疫系统功能失常的遗传疾病；以及丙酮酸激酶缺乏症，这是一种罕见的红细胞常染色体隐性遗传病，导致慢性非球形溶血性贫血。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们认为比 Rocket Pharmaceuticals 更好的股票</li>
<li>哪里可以找到财报电话会议记录</li>
<li>Sandisk 在 118% 的 AI 推动上涨后仍然值得购买吗？</li>
<li>投资建筑类股票</li>
<li>为什么 GlobalFoundries 刚刚成为地缘政治的权力游戏</li>
<li>什么是认沽期权成交量？</li>
<li>3 只通过回购推动可持续价格增长的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Rocket Pharmaceuticals 吗？</h2>
<p>在你考虑 Rocket Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而 Rocket Pharmaceuticals 并不在名单上。</p>
<p>虽然 Rocket Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Rocket制药

<p>Leerink Partners 已将 Rocket Pharmaceuticals（NASDAQ:RCKT）的目标价从 9.00 美元下调至 7.00 美元，维持 “市场表现” 评级。此调整表明，相较于该股前一交易日的收盘价，潜在上涨幅度为 118.41%。其他分析师也调整了他们的目标价，瑞银集团设定的目标为 5.00 美元，加拿大皇家银行的目标为 10.00 美元。目前，Rocket Pharmaceuticals 的平均评级为 “持有”，共识目标价为 16.67 美元。该股交易价格为 3.21 美元，市值为 3.4582 亿美元</p>

<p>Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) had its target price cut by investment analysts at Leerink Partners from $9.00 to $7.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a &#34;market perform&#34; rating on the biotechnology company's stock. Leerink Partners' target price points to a potential upside of 118.41% from the stock's previous close.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals（纳斯达克代码：RCKT - 获取免费报告）在周五向客户和投资者发布的研究报告中，投资分析师 Leerink Partners 将其目标价格从 9.00 美元下调至 7.00 美元，Benzinga 报道。该券商目前对这家生物技术公司的股票给予 “市场表现” 评级。Leerink Partners 的目标价格意味着该股票相较于之前的收盘价有 118.41% 的潜在上涨空间。</p>
</div><p>Get <strong>Rocket Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Rocket Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>3 Small-Cap Stocks That Are Ready to Rocket Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只准备大幅上涨的小型股</li>
</ul>
</div><p>A number of other equities analysts have also commented on RCKT. UBS Group reduced their price target on shares of Rocket Pharmaceuticals from $12.00 to $5.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, June 17th. Canaccord Genuity Group decreased their price objective on shares of Rocket Pharmaceuticals from $11.00 to $10.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, July 25th. Chardan Capital reissued a &#34;buy&#34; rating and set a $11.00 price objective on shares of Rocket Pharmaceuticals in a report on Wednesday, August 20th. Bank of America raised shares of Rocket Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and increased their price objective for the stock from $4.00 to $10.00 in a report on Wednesday, August 20th. Finally, Needham &amp; Company LLC reissued a &#34;hold&#34; rating on shares of Rocket Pharmaceuticals in a report on Thursday, July 24th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Hold&#34; and a consensus price target of $16.67.</p>
<div class="lb-trans"><p>其他一些股票分析师也对 RCKT 发表了评论。瑞银集团将 Rocket Pharmaceuticals 的目标价格从 12.00 美元下调至 5.00 美元，并在 6 月 17 日的研究报告中对该股票给予 “买入” 评级。Canaccord Genuity Group 将 Rocket Pharmaceuticals 的目标价格从 11.00 美元下调至 10.00 美元，并在 7 月 25 日的报告中对该股票给予 “买入” 评级。Chardan Capital 在 8 月 20 日的报告中重申了对 Rocket Pharmaceuticals 的 “买入” 评级，并设定了 11.00 美元的目标价格。美国银行在 8 月 20 日的报告中将 Rocket Pharmaceuticals 的评级从 “中性” 上调至 “买入”，并将该股票的目标价格从 4.00 美元提高至 10.00 美元。最后，Needham &amp; Company LLC 在 7 月 24 日的报告中重申了对 Rocket Pharmaceuticals 的 “持有” 评级。八位股票研究分析师对该股票给予 “买入” 评级，八位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “持有”，共识目标价格为 16.67 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on RCKT</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 RCKT 股票分析</strong></p>
</div><h2>Rocket Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 股票表现</h2>
</div><p>Rocket Pharmaceuticals stock traded down $0.01 on Friday, hitting $3.21. The company's stock had a trading volume of 623,434 shares, compared to its average volume of 3,511,637. The firm has a market cap of $345.82 million, a P/E ratio of -1.28 and a beta of 0.60. The company has a quick ratio of 6.39, a current ratio of 6.39 and a debt-to-equity ratio of 0.05. The company has a fifty day moving average price of $3.19 and a 200-day moving average price of $4.37. Rocket Pharmaceuticals has a one year low of $2.19 and a one year high of $18.89.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals 的股票在周五下跌 0.01 美元，报 3.21 美元。该公司的股票交易量为 623,434 股，而其平均交易量为 3,511,637 股。该公司的市值为 3.4582 亿美元，市盈率为-1.28，贝塔值为 0.60。该公司的速动比率为 6.39，流动比率为 6.39，债务与股本比率为 0.05。该公司的 50 日移动平均价格为 3.19 美元，200 日移动平均价格为 4.37 美元。Rocket Pharmaceuticals 的股价在过去一年内最低为 2.19 美元，最高为 18.89 美元。</p>
</div><p>Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.02). During the same period last year, the company earned ($0.74) EPS. On average, equities analysts anticipate that Rocket Pharmaceuticals will post -2.83 earnings per share for the current year.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals（纳斯达克代码：RCKT - 获取免费报告）最近一次发布财报是在 8 月 7 日。该生物技术公司报告本季度每股收益为（0.59 美元），低于市场共识预期的（0.57 美元），差额为（0.02 美元）。去年同期，该公司每股收益为（0.74 美元）。分析师平均预计 Rocket Pharmaceuticals 在本年度的每股收益为-2.83 美元。</p>
</div><h2>Insider Activity at Rocket Pharmaceuticals</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 的内部活动</h2>
</div><p>In related news, insider Jonathan David Schwartz sold 11,161 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $3.02, for a total value of $33,706.22. Following the sale, the insider directly owned 224,094 shares in the company, valued at $676,763.88. This trade represents a 4.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Martin Wilson sold 12,109 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $3.02, for a total transaction of $36,569.18. Following the completion of the sale, the general counsel owned 137,054 shares in the company, valued at $413,903.08. This represents a 8.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,450 shares of company stock worth $107,159 in the last ninety days. Company insiders own 24.76% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Jonathan David Schwartz 在 8 月 14 日的交易中出售了 11,161 股该股票。这些股票的平均售价为 3.02 美元，总价值为 33,706.22 美元。出售后，该内部人士直接持有 224,094 股公司股票，价值 676,763.88 美元。这笔交易代表其持股比例减少了 4.74%。该出售在向 SEC 的法律文件中披露，文件可在此链接查看。此外，首席法律顾问 Martin Wilson 在 8 月 14 日的交易中出售了 12,109 股该股票。这些股票的平均售价为 3.02 美元，总交易额为 36,569.18 美元。出售完成后，首席法律顾问持有 137,054 股公司股票，价值 413,903.08 美元。这代表其持股比例减少了 8.12%。该出售的披露信息可以在这里找到。在过去的九十天里，内部人士共出售了价值 107,159 美元的 35,450 股公司股票。公司内部人士持有公司股票的 24.76%。</p>
</div><h2>Institutional Trading of Rocket Pharmaceuticals</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 的机构交易</h2>
</div><p>Several hedge funds have recently bought and sold shares of the stock. Victory Capital Management Inc. lifted its holdings in shares of Rocket Pharmaceuticals by 16.1% during the first quarter. Victory Capital Management Inc. now owns 11,929 shares of the biotechnology company's stock worth $80,000 after buying an additional 1,658 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Rocket Pharmaceuticals by 8.4% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 21,885 shares of the biotechnology company's stock valued at $146,000 after purchasing an additional 1,689 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Rocket Pharmaceuticals by 10.7% in the first quarter. China Universal Asset Management Co. Ltd. now owns 21,388 shares of the biotechnology company's stock valued at $143,000 after purchasing an additional 2,059 shares in the last quarter. HighTower Advisors LLC raised its stake in Rocket Pharmaceuticals by 16.6% in the first quarter. HighTower Advisors LLC now owns 20,700 shares of the biotechnology company's stock valued at $138,000 after purchasing an additional 2,952 shares in the last quarter. Finally, Arizona State Retirement System raised its stake in Rocket Pharmaceuticals by 15.3% in the first quarter. Arizona State Retirement System now owns 22,852 shares of the biotechnology company's stock valued at $152,000 after purchasing an additional 3,026 shares in the last quarter. 98.39% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>最近，一些对冲基金买入和卖出了该股票的股份。Victory Capital Management Inc.在第一季度将其在 Rocket Pharmaceuticals 的持股增加了 16.1%。Victory Capital Management Inc.现在拥有 11,929 股该生物技术公司的股票，价值 80,000 美元，此前在上个季度又购买了 1,658 股。三菱 UFJ 资产管理有限公司在第一季度将其在 Rocket Pharmaceuticals 的持股增加了 8.4%。三菱 UFJ 资产管理有限公司现在拥有 21,885 股该生物技术公司的股票，价值 146,000 美元，此前在上个季度又购买了 1,689 股。中国泛海资产管理有限公司在第一季度将其在 Rocket Pharmaceuticals 的持股增加了 10.7%。中国泛海资产管理有限公司现在拥有 21,388 股该生物技术公司的股票，价值 143,000 美元，此前在上个季度又购买了 2,059 股。HighTower Advisors LLC 在第一季度将其在 Rocket Pharmaceuticals 的持股增加了 16.6%。HighTower Advisors LLC 现在拥有 20,700 股该生物技术公司的股票，价值 138,000 美元，此前在上个季度又购买了 2,952 股。最后，亚利桑那州退休系统在第一季度将其在 Rocket Pharmaceuticals 的持股增加了 15.3%。亚利桑那州退休系统现在拥有 22,852 股该生物技术公司的股票，价值 152,000 美元，此前在上个季度又购买了 3,026 股。目前 98.39% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Rocket Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals, Inc 及其子公司是一家处于后期阶段的生物技术公司，专注于开发针对罕见且严重疾病的基因疗法。它拥有三个临床阶段的外源性慢病毒载体项目，分别针对范可尼贫血，这是一种导致骨髓中血细胞生产减少或产生有缺陷血细胞的遗传缺陷；白细胞粘附缺陷-I，这是一种导致免疫系统功能失常的遗传疾病；以及丙酮酸激酶缺乏症，这是一种罕见的红细胞常染色体隐性遗传病，导致慢性非球形溶血性贫血。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Rocket Pharmaceuticals</li>
<li>Where to Find Earnings Call Transcripts</li>
<li>Is Sandisk Still a Buy After 118% AI-Fueled Surge?</li>
<li>Investing in Construction Stocks</li>
<li>Why GlobalFoundries Just Became a Geopolitical Power Play</li>
<li>What is Put Option Volume?</li>
<li>3 Stocks Using Buybacks to Drive Sustainable Price Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Rocket Pharmaceuticals 更好的股票</li>
<li>哪里可以找到财报电话会议记录</li>
<li>Sandisk 在 118% 的 AI 推动上涨后仍然值得购买吗？</li>
<li>投资建筑类股票</li>
<li>为什么 GlobalFoundries 刚刚成为地缘政治的权力游戏</li>
<li>什么是认沽期权成交量？</li>
<li>3 只通过回购推动可持续价格增长的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=RCKT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rocket Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Rocket Pharmaceuticals 吗？</h2>
</div><p>Before you consider Rocket Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Rocket Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rocket Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而 Rocket Pharmaceuticals 并不在名单上。</p>
</div><p>While Rocket Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rocket Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Leerink Partners 的分析师将 Rocket 制药（NASDAQ:RCKT）的目标价下调至 7.00 美元